Table 5.
Studies (more than 40 patients) reporting frequencies of MD in PCNSL
| Author | Patients with CSF/all patients | % MD positive | Diagnostic methods (% positive) | Prior steroid use | Prognostic impact on OAS |
|---|---|---|---|---|---|
| Abrey et al.20 | 279/338 | 17 | Cytomorphologic examination | Not reported | No impact |
| Ferreri et al.2 | 241/378 | 18 | Cytomorphologic examination | Not reported | No impact for cytomorphologic proof |
| Negative impact for CSF protein >450 mg/l | |||||
| Blay et al.32 | 157/226 | 16 | Cytomorphologic examination | Not reported | Negative impact for CSF protein >600 mg/l and positive cytomorphology (univariate) |
| Fischer et al.33 | 116/145 | 18 | Cytomorphologic examination | 71/91 with available data | Not evaluated |
| Balmaceda et al.7 | 86/96 | 42 | Cytomorphologic examination (27%), imaging, meningeal biopsy | 56/69 with available data | No impact |
| DeAngelis et al.34 | 81/98 | 21 | Cytomorphologic examination | Not reported | Not evaluated |
| Gleissner et al.17 | 76/76 | 16 | Cytomorphologic examination (8%), CDR III PCR (11%) | 60/68 | Not evaluated |
| Present study | 69/92 | 16 | Cytomorphologic examination (11%), immunophenotyping (3%), CDR III PCR (16%) | 13/23 with available data | Negative impact for positive cytomorphology only |
| Pels et al.12 | 58/65 | 12 | Cytomorphologic examination | Not reported | Not evaluated |
| Gavrilovic et al.35 | 57/57 | 18 | Cytomorphologic examination | Not reported | Not evaluated |
| Abrey et al.36 | 52/52 | 21 | Cytomorphologic examination | Not reported | Not evaluated |
| Hoang-Xuan et al.37 | 50/50 | 18 | Not reported | Not reported | Not evaluated |
| Korfel et al.14 | 45/60 | 18 | Cytomorphologic examination | Not reported | No impact |
| Poortmans et al.38 | 43/52 | 16 | Not reported | Not reported | Not evaluated |
| O'Brien et al.39 | 42/46 | 7 | Cytomorphologic examination, immunophenotyping | Not reported | Not evaluated |
Abbreviations: OAS, overall survival; CSF, cerebrospinal fluid.